RESUMO
The objective of this study was to determine whether cerebrospinal fluid(CSF)-corrected concentrations of N-acetylaspartate are lower in several brain regions of drug- and medication-free subjects with bipolar disorder as compared with matched healthy controls. Bipolar subjects (n=21) and age- and sex-matched healthy control (n=21) were studied using proton magnetic resonance spectroscopic imaging on a 3T magnetic resonance (MR) scanner. Spectra were quantified using the LCModel, and metabolite values were CSF-corrected to yield metabolite concentrations. Fourteen regions of interest and five metabolite concentrations in each subject were selected for statistical analysis. We found that bipolar subjects had significantly decreased N-acetylaspartate concentrations in both caudate heads and the left lentiform nucleus. Choline and creatine in the head of the right caudate were also significantly decreased in bipolar subjects. Significantly increased myo-inositol was found in the left caudate head in bipolar subjects. Bipolar subjects showed significantly decreased glutamate/glutamine concentrations in the frontal white matter bilaterally and in the right lentiform nucleus. No differences were found for other metabolites examined. These preliminary findings suggest decreased neuronal density or viability in the basal ganglia and neurometabolic abnormalities in the frontal lobes of subjects with bipolar disorder.
Assuntos
Transtorno Bipolar/líquido cefalorraquidiano , Encéfalo/fisiopatologia , Metabolismo Energético/fisiologia , Processamento de Imagem Assistida por Computador , Imageamento por Ressonância Magnética , Espectroscopia de Ressonância Magnética , Adolescente , Adulto , Ácido Aspártico/análogos & derivados , Ácido Aspártico/líquido cefalorraquidiano , Gânglios da Base/fisiopatologia , Transtorno Bipolar/diagnóstico , Estudos de Casos e Controles , Núcleo Caudado/fisiopatologia , Corpo Estriado/fisiopatologia , Creatina/líquido cefalorraquidiano , Estudos Transversais , Dominância Cerebral/fisiologia , Feminino , Lobo Frontal/fisiopatologia , Ácido Glutâmico/líquido cefalorraquidiano , Glutamina/líquido cefalorraquidiano , Humanos , Inositol/líquido cefalorraquidiano , Masculino , Pessoa de Meia-Idade , Valores de ReferênciaRESUMO
Deficiency of guanidinoacetate methyltransferase (GAMT), the first described creatine biosynthesis defect, leads to depletion of creatine and phosphocreatine, and accumulation of guanidinoacetate in brain. This results in epilepsy, mental retardation, and extrapyramidal movement disorders. Investigation of skeletal muscle by proton and phosphorus magnetic resonance spectroscopy before therapy demonstrated the presence of considerable amounts of creatine and phosphocreatine, and accumulation of phosphorylated guanidinoacetate in a 7-year-old boy diagnosed with GAMT deficiency, suggesting separate mechanisms for creatine uptake and synthesis in brain and skeletal muscle. The combination of creatine supplementation and a guanidinoacetate-lowering therapeutic approach resulted in improvement of clinical symptoms and metabolite concentrations in brain, muscle, and body fluids.
Assuntos
Encéfalo/metabolismo , Creatina/metabolismo , Glicina/análogos & derivados , Metiltransferases/deficiência , Músculo Esquelético/metabolismo , Arginina/sangue , Criança , Creatina/líquido cefalorraquidiano , Creatina/uso terapêutico , Creatinina/sangue , Creatinina/urina , Cromatografia Gasosa-Espectrometria de Massas , Glicina/sangue , Glicina/líquido cefalorraquidiano , Glicina/urina , Guanidinoacetato N-Metiltransferase , Humanos , Espectroscopia de Ressonância Magnética , Masculino , Ornitina/sangue , Fosfocreatina/metabolismo , TurquiaRESUMO
Guanidinoacetate methyltransferase (GAMT) deficiency (McKusick 601240), an inborn error of creatine biosynthesis, is characterized by creatine depletion and accumulation of guanidinoacetate (GAA) in the brain. Treatment by oral creatine supplementation had no effect on the intractable seizures. Based on the possible role of GAA as an epileptogenic agent, we evaluated a dietary treatment with arginine restriction and ornithine supplementation in order to achieve reduction of GAA. In an 8-year-old Kurdish girl with GAMT deficiency arginine intake was restricted to 15 mg/kg/day (0.4 g natural protein/kg/day) and ornithine was supplemented with 100 mg/kg/day over a period of 14 months. The diet was enriched with 0.4 g/kg/day of arginine-free essential amino acid mixture and creatine treatment remained unchanged (1.1 g/kg/day). Guanidino compounds in blood, urine, and CSF were measured by means of cation-exchange chromatography. The combination of arginine restriction and ornithine supplementation led to a substantial and permanent decrease of arginine without disturbance of nitrogen detoxification. Formation of GAA was effectively reduced after 4 weeks of treatment and sustained thereafter. Biochemical effects were accompanied by a marked clinical improvement. Distinctly reduced epileptogenic activities in electroencephalography accompanied by almost complete disappearance of seizures demonstrates the positive effect of GAA reduction. This indicates for the first time that GAA may exert an important epileptogenic potential in man. Arginine restriction in combination with ornithine supplementation represents a new and rationale therapeutic approach in GAMT deficiency.